• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>DRS

DRS

  1. All
  2. 3rd Party
  3. Investing
  1. RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea

    RegeneRx's RGN-259 Meets Key Efficacy Objectives in Phase 2 Clinical Trial in Patients with Severe Dry Eye Reported in Current Issue of Cornea

  2. Pressure BioSciences Announces the Release of PCT-HD, "The Next Generation Protein Preparation System"

    Pressure BioSciences Announces the Release of PCT-HD, "The Next Generation Protein Preparation System"

  3. AbbVie And C2N Enter Into A Worldwide License Agreement For Alzheimer's Disease Therapy

    AbbVie And C2N Enter Into A Worldwide License Agreement For Alzheimer's Disease Therapy

  4. Research and Markets: Global Non-Lethal Weapons Market 2014-2020 - Analysis of Key Players, Raytheon, BAE Systems, LRAD, Eagle Industries & Taser International

    Research and Markets: Global Non-Lethal Weapons Market 2014-2020 - Analysis of Key Players, Raytheon, BAE Systems, LRAD, Eagle Industries & Taser International

  5. Roger Ibbotson, Benoit Mandelbrot, and George Cooper

    Our distinguished economics panel debates the value of current risk models.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.